Close

Dr Fern Terris-Prestholt

MSc PhD

Associate Professor
in Economics of HIV

Room
340

LSHTM
15-17 Tavistock Place
London
WC1H 9SH
United Kingdom

Tel.
+44 (0)207 927 2271

Fern Terris-Prestholt joined Social and Mathematical Epidemiology (SaME) in the Department of Global Health and Development 2000.

Fern's main area of research are around the economics of preferences and behaviour of HIV prevention.  Her core work also spans economic evalution of HIV interventions.  These areas come together by using discrete choice experiments to both inform the design of HIV interventions to improve uptake and targetting. DCEs are also used to parameterise uptake in cost effectiveness modelling. 

She completed her PhD on Introduction and Distribution of New Barrier Methods for HIV prevention, which focussed primarily on women's demand for microbicidein South Africa. She holds a MSc in Development Economics from Wageningen University, The Netherlands and a B.A. from Macalester College in St. Paul, MN, USA. She previously worked at the Institute for Medical Technology Assessment in Rotterdam, The Netherlands.

 

Affiliations

Faculty of Public Health and Policy
Department of Global Health and Development

Teaching

Course organiser: Economic analysis for health policy

Seminar leader: Introduction to health economics

Guest lectures on economic evaluation of reproductive health / HIV interventions on a range of courses both within and outside of LSHTM.

 

Fern would welcome PhD students with a foundation in economics with an interest in the demand for HIV prevention, using methods such as discrete choice experiments or behavioural economics approaches.

Research

Fern is part of SaME (Social and Mathematical Epidemioloty) _ HIV modelling and Economics subgroup, which is a group of economists and mathematical modellers who use modelling and economic analysis to inform HIV/AIDS policy.

http://blogs.lshtm.ac.uk/samemodellingandeconomics/

Her work focuses on the the economics of new technology introduction for the prevention, diagnosis and treatment of HIV and related conditions (such as STIs), primarily in low and middle income countries.  Her PhD studied the determinants of women's demand for barrier methods for HIV prevention in South Africa.

Current projects: 

  • The STAR project: developing distribution strategies for Oral HIV self tests in Malawi, Zimbabwe, Zambia, South Africa, Lesoth and Swaziland. Her role is to lead the research on user preferences as well as costing to inform the development of optimal distribution systems.
  • She lead economist in OPTIONS, supporting the introduction of new ARV based HIV prevention products for women.
  • Using crowdsourcing to develop campaigns to stimulate demand for HIV testing among MSM in Chinaing
  • Stimulating demand for Voluntary Medical Male Circumcision in Tanzania: using discrete choice experiments to inform intervention design

She has worked on a number of other HIV/STI prevention projects in Africa, Asia and Latin America and the UK in recent years:

  • ARV-based Prevention: We modelled the cost-effectiveness of Pre-exposure Profylaxis, Treatment as Prevention, and potential future products, in Nigeria. It was part of an international collaboration coordinated by Georgetown University and funded by Gates. Other mathematical modellers and economists were working in Kenya and South Africa. 
  • Assessing Youth Preferences for Integrated Mobile HIV and Family Planning Services in Rural Malawi: This project aimed to inform the roll out of youth targeted mobile reproductive and sexual health services provided by the Family Planning Association of Malawi. It was a 5 year project that is finishing this year (2013). 
  • Understanding economies of scope and scale of integrating HIV treatment and care in family planning and post-natal care services in Kenya, Swaziland and Malawi as part of the 5 year Gates funded project: Assesing the benefits and costs of integrating HIV services into family planning and post natal care services in Kenya, Swaziland and Malawi.
  • Estimating the costs and cost effectiveness of introducing rapid syphilis screening tests in hard to reach populations in Brazil, Tanzania and China and estimating the costs of scaling up. This is a 3 year Gates/WHO funded project which is very much country driven. I provide the support to local researchers to assist their economic analysis. 
  • Effectiveness of HIV screening in Primary Care: a clustered randomised controlled trial and economic analysis. This study looks at provider initiated HIV screening at registration with GP practices in Hackney, an area of London which hosts many new migrants.

Together these studies contribute to a body of work on the uptake and introduction of new technologies.

In 2015, she took a study leave at the Dalla Lana School of Public Health at the University of Toronto, where she worked on a paper estimating the dynamic effects of condom social marketting tools on uptake of male and female condoms (Journal of Heath Economics) and another paper considering the role of discrete choice experiment as part of formative research for complex interventions.

Main methodologies used:

cost-effectiveness analysis, discrete choice experiments to estimate new uptake, and econometric analysis.

Research Area
Complex interventions
Diagnostics
Economic evaluation
Health policy
Maternal health
Sexual health
Behaviour change
Capacity strengthening
Equity
Evaluation
Global Health
Health services
Implementation research
Reproductive health
Modelling
Discipline
Health economics
Economics
Disease and Health Conditions
Syphilis
HIV/AIDS
Sexually transmitted disease
Human papillomavirus (HPV)
Sexually transmitted infection
Region
East Asia & Pacific (developing only)
Least developed countries: UN classification
Sub-Saharan Africa (all income levels)

Selected Publications

The promise of multipurpose pregnancy, STI, and HIV prevention.
Quaife, M. ; Terris-Prestholt, F. ; Vickerman, P. ;
2017
Lancet Infect Dis
Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments.
Terris-Prestholt, F.; Quaife, M.; Vickerman, P.;
2016
Health Econ
The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia.
Terris-Prestholt, F.; Vickerman, P.; Torres-Rueda, S.; Santesso, N.; Sweeney, S.; Mallma, P.; Shelley, K.D.; Garcia, P.J.; Bronzan, R.; Gill, M.M.; Broutet, N.; Wi, T.; Watts, C.; Mabey, D.; Peeling, R.W.; Newman, L.;
2015
Int J Gynaecol Obstet
Sustainable HIV treatment in Africa through viral-load-informed differentiated care.
Phillips, A. ; Shroufi, A. ; Vojnov, L. ; Cohn, J. ; Roberts, T. ; Ellman, T. ; Bonner, K. ; Rousseau, C. ; Garnett, G. ; Cambiano, V. ; Nakagawa, F. ; Ford, D. ; Bansi-Matharu, L. ; Miners, A. ; Lundgren, J.D. ; Eaton, J.W. ; Parkes-Ratanshi, R. ; Katz, Z. ; Maman, D. ; Ford, N. ; Vitoria, M. ; Doherty, M. ; Dowdy, D. ; Nichols, B. ; Murtagh, M. ; Wareham, M. ; Palamountain, K.M. ; Chakanyuka Musanhu, C. ; Stevens, W. ; Katzenstein, D. ; Ciaranello, A. ; Barnabas, R. ; Braithwaite, R.S. ; Bendavid, E. ; Nathoo, K.J. ; van de Vijver, D. ; Wilson, D.P. ; Holmes, C. ; Bershteyn, A. ; Walker, S. ; Raizes, E. ; Jani, I. ; Nelson, L.J. ; Peeling, R. ; Terris-Prestholt, F. ; Murungu, J. ; Mutasa-Apollo, T. ; Hallett, T.B. ; Revill, P. ;
2015
Nature
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Terris-Prestholt, F. ; Foss, A.M. ; Cox, A.P. ; Heise, L. ; Meyer-Rath, G. ; Delany-Moretlwe, S. ; Mertenskoetter, T. ; Rees, H. ; Vickerman, P. ; Watts, C.H. ;
2014
BMC Infect Dis
See all Dr Fern Terris-Prestholt's Publications